Echocardiographic phenotype for refined risk stratification and treatment selection in light chain amyloidosis with heart failure

被引:1
作者
Yang, Hong [1 ,2 ]
Li, Rui [1 ,2 ]
Ma, Fei [1 ,2 ]
Liu, Yujian [1 ,2 ]
He, Xingwei [1 ,2 ]
Yang, Qiao [1 ,2 ]
Wang, Dao Wen [1 ,2 ]
Zeng, Hesong [1 ,2 ]
Wang, Hong [1 ,2 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Div Cardiol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
[2] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Internal Med, 1095 Jiefang Ave, Wuhan 430030, Peoples R China
关键词
Light chain amyloidosis; Cardiac amyloidosis; Heart failure; Mayo staging system; Echocardiography; SPECKLE-TRACKING ECHOCARDIOGRAPHY; PRIMARY SYSTEMIC AMYLOIDOSIS; CORONARY-ARTERY-DISEASE; LONGITUDINAL STRAIN; NATRIURETIC PEPTIDE; CARDIAC AMYLOIDOSIS; AMERICAN-SOCIETY; STAGING SYSTEM; TASK-FORCE; AL;
D O I
10.1007/s00432-023-04783-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
AimsLight chain amyloidosis (AL) patients with heart failure (HF) are usually with revised Mayo (rMayo) stage III/IV disease and have a poor prognosis. We sought to investigate whether and what echocardiographic phenotype provides value for further risk stratification and guiding optimal risk-adapted treatment in this subgroup of AL patients.Methods and Results95 AL patients who presented with HF and were on rMayo stage III/IV were retrospectively included. Of them, 51 patients (53.7%) were with stage III, 44 (46.3%) were with stage IV, and 44 (46.3%) underwent chemotherapy. Laboratory and echocardiographic measurements were acquired before the initiation of chemotherapy. The relevance of different variables with survival was assessed in the entire cohort, chemotherapy, and non-chemotherapy group. By Multivariate Cox regression analysis, right ventricular wall thickness (RVT) [HR 1.145, 95% confidence interval (CI) 1.026-1.279, P = 0.016], relative wall thickness (RWT) (HR 6.709, 95% CI 1.101-40.877, P = 0.039), and left ventricular ejection fraction (LVEF) < 50% (HR 1.939, 95% CI 1.048-3.590, P = 0.035) were found to be independently associated with survival in the entire cohort, RWT (HR 15.488, 95% CI 2.045-117.292, P = 0.008) in the non-chemotherapy group, and RVT (HR 1.331, 95% CI 1.054-1.681, P = 0.016) in the chemotherapy group, respectively. Kaplan-Meier survival analysis revealed that survival was significantly reduced in the presence of RVT >= 6.5 mm or LVEF < 50% in the entire cohort, and the significance of RVT >= 6.5 mm was irrespective of rMayo stages. In the chemotherapy group, survival was decreased if RVT >= 6.5 mm alone or together with RWT >= 0.67 were present, particularly in patients on rMayo stage IV.ConclusionsEchocardiographic phenotype provides incremental value beyond rMayo staging for predicting survival and could further guide treatment in advanced AL with HF. Those with high-risk echocardiographic phenotypes as higher RVT and RWT and lower LVEF had a worse prognosis.
引用
收藏
页码:8415 / 8427
页数:13
相关论文
共 45 条
  • [1] Prognostic restaging after treatment initiation in patients with AL amyloidosis
    Abdallah, Nadine
    Dispenzieri, Angela
    Muchtar, Eli
    Buadi, Francis K.
    Kapoor, Prashant
    Lacy, Martha Q.
    Hwa, Yi L.
    Fonder, Amie
    Hobbs, Miriam A.
    Hayman, Suzanne R.
    Leung, Nelson
    Dingli, David
    Lust, John A.
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson, I
    Kourelis, Taxiarchis
    Warsame, Rahma
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kumar, Shaji K.
    [J]. BLOOD ADVANCES, 2021, 5 (04) : 1029 - 1036
  • [2] Standardization of left atrial, right ventricular, and right atrial deformation imaging using two-dimensional speckle tracking echocardiography: a consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging
    Badano, Luigi P.
    Kolias, Theodore J.
    Muraru, Denisa
    Abraham, Theodore P.
    Aurigemma, Gerard
    Edvardsen, Thor
    D'Hooge, Jan
    Donal, Erwan
    Fraser, Alan G.
    Marwick, Thomas
    Mertens, Luc
    Popescu, Bogdan A.
    Sengupta, Partho P.
    Lancellotti, Patrizio
    Thomas, James D.
    Voigt, Jens-Uwe
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2018, 19 (06) : 591 - 600
  • [3] Prognosis of Light Chain Amyloidosis With Preserved LVEF Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System
    Barros-Gomes, Sergio
    Williams, Brittney
    Nhola, Lara F.
    Grogan, Martha
    Maalouf, Joseph F.
    Dispenzieri, Angela
    Pellikka, Patricia A.
    Villarraga, Hector R.
    [J]. JACC-CARDIOVASCULAR IMAGING, 2017, 10 (04) : 398 - 407
  • [4] Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival
    Basset, Marco
    Milani, Paolo
    Foli, Andrea
    Nuvolone, Mario
    Benvenuti, Pietro
    Nanci, Martina
    Fabris, Francesca
    Bellofiore, Claudia
    Merlini, Giampaolo
    Palladini, Giovanni
    [J]. BLOOD, 2022, 140 (18) : 1964 - 1971
  • [5] Serum-free light-chain assay: clinical utility and limitations
    Bhole, Malini V.
    Sadler, Ross
    Ramasamy, Karthik
    [J]. ANNALS OF CLINICAL BIOCHEMISTRY, 2014, 51 (05) : 528 - 542
  • [6] Right ventricutlar function in AL amyloidosis: characteristics and prognostic implication
    Cappelli, Francesco
    Porciani, Maria Cristina
    Bergesio, Franco
    Perlini, Stefano
    Attana, Paola
    Pignone, Alberto Moggi
    Salinaro, Francesco
    Musca, Francesco
    Padeletti, Luigi
    Perfetto, Federico
    [J]. EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 2012, 13 (05) : 416 - 422
  • [7] Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis
    Cohen, Oliver C.
    Ismael, Andreia
    Pawarova, Babita
    Manwani, Richa
    Ravichandran, Sriram
    Law, Steven
    Foard, Darren
    Petrie, Aviva
    Ward, Sevda
    Douglas, Brooke
    Martinez-Naharro, Ana
    Chacko, Liza
    Quarta, Candida Cristina
    Mahmood, Shameem
    Sachchithanantham, Sajitha
    Lachmann, Helen J.
    Hawkins, Philip N.
    Gillmore, Julian D.
    Fontana, Marianna
    Falk, Rodney H.
    Whelan, Carol J.
    Wechalekar, Ashutosh D.
    [J]. EUROPEAN HEART JOURNAL, 2022, 43 (04) : 333 - 341
  • [8] Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients
    Comenzo, RL
    Vosburgh, E
    Simms, RW
    Bergethon, P
    Sarnacki, D
    Finn, K
    Dubrey, S
    Faller, DV
    Wright, DG
    Falk, RH
    Skinner, M
    [J]. BLOOD, 1996, 88 (07) : 2801 - 2806
  • [9] POOR R-WAVE PROGRESSION IN THE PRECORDIAL LEADS - CLINICAL IMPLICATIONS FOR THE DIAGNOSIS OF MYOCARDIAL-INFARCTION
    DEPACE, NL
    COLBY, J
    HAKKI, AH
    MANNO, B
    HOROWITZ, LN
    ISKANDRIAN, AS
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1983, 2 (06) : 1073 - 1079
  • [10] Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
    Dispenzieri, A
    Gertz, MA
    Kyle, RA
    Lacy, MQ
    Burritt, MF
    Therneau, TM
    Greipp, PR
    Witzig, TE
    Lust, JA
    Rajkumar, SV
    Fonseca, R
    Zeldenrust, SR
    McGregor, CGA
    Jaffe, AS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3751 - 3757